SHANGHAI, Oct. 28, 2025 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contrac...
* Q3 Total Revenue: RMB12.06 Billion, Up 15.3% YoY; * Revenue from Continuing Operations[1] Reac...
SHANGHAI, Sept. 21, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a ...
SHANGHAI, Sept. 8, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfol...
SHANGHAI, Aug. 5, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfoli...
SHANGHAI, July 7, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock codes: 603259.SH/2359.HK), a gl...
SHANGHAI, July 7, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfoli...
SHANGHAI, June 26, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfol...
SHANGHAI, June 17, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfol...
SHANGHAI, June 16, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfol...
* Total Revenue Reached RMB9.65 Billion, Up 21.0% Year-over-Year; among which Revenue from Contin...
* Fourth-Quarter Revenue Reached RMB11,539 Million, Up 6.9% Year-over-Year * 2024 Revenue Reache...
SHANGHAI, Jan. 12, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfol...
SHANGHAI, Dec. 30, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfol...
SHANGHAI, Nov. 11, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfol...
SHANGHAI, Oct. 29, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfol...
* Revenue Reached RMB10,461 Million in the Third Quarter, Excluding COVID-19 Commercial Projects,...
* Revenue Reached RMB9,259 Million in the Second Quarter, Excluding COVID-19 Commercial Projects,...
* Revenue Reached RMB7,982 Million; Excluding COVID-19 Commercial Projects, Down 1.8% * Net Pro...
* Revenue Up 2.5% Year-over-Year to RMB40,341 Million; Excluding COVID-19 Commercial Projects, Up...